Discussion Topic: Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women’s Hospital, is joined by guests Michael G. Katz, MD, FHRS, of Morristown Medical Center and Victor Nauffal, MD, of Brigham and Women`s Hospital, to discuss the treatment options for high-risk Brugada syndrome (BrS) with recurrent ventricular fibrillation (VF) and how it is limited. Catheter ablation is increasingly performed, but a large study with long-term outcome data is lacking. We report the results of the multicenter, international BRAVO (Brugada Ablation of VF Substrate Ongoing Registry) for treatment of high-risk symptomatic BrS. Ablation treatment is safe and highly effective in preventing VF recurrence in high-risk BrS. Prospective studies are needed to determine whether it can be an alternative treatment to implantable cardioverter-defibrillator implantation for selected patients with BrS.
Host: William H. Sauer, MD, FHRS, CCDS
Guests: Michael G. Katz, MD, FHRS and Victor Nauffal, MD
Speaker and Article Information: Download
Topic
- The Lead
Resource Type
- Podcasts
Related Resources
The Lead
Podcasts
The Lead Episode 143: A Discussion of The Empirical Evidence in the Successful Anatomical Ablation of Idiopathic LV Summit Ventricular Arrhythmias
April 9, 2026
The Lead
Podcasts
The Lead Episode 142: A Discussion of Class 1c Antiarrhythmic Therapy Following PCI in New Onset Atrial Fibrillation: Safety and Clinical Outcomes from a Nationwide Cohort
April 2, 2026
The Lead
Podcasts
The Lead Episode 141: A Discussion of Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis
March 19, 2026